Orion (HLSE:ORNBV) Stock May Trade At A 49% Discount On Cash Flow

Orion Oyj has delivered a powerful share price story in recent years, which naturally raises a question for anyone looking at the stock today. Given that the current valuation lens is its cash flows, the real issue is whether the recent gain is fully supported by the cash the business can generate over time.

• Over the past 5 years the Orion Oyj share price has returned 169.7%, which puts a lot of weight on whether that move matches what its cash flows can justify.
• The group relies on turning pharmaceutical research into durable products and recurring revenue, so the strength and predictability of those cash streams may support or constrain what investors are willing to pay today.
• What if you looked at Orion Oyj through its earnings instead? See what Orion Oyj's 19.6x P/E says about the price.

The issue now is whether the current Orion Oyj share price of €81.5 is in line with what its cash flows suggest the stock is intrinsically worth.

If you want to weigh Orion Oyj against other opportunities through the same cash flow lens, compare it with companies in the 180 high quality undervalued stocks

Is Orion Oyj a Bargain on Cash Flow?

The Discounted Cash Flow, or DCF, model here is built on Orion Oyj’s own cash generation rather than accounting profit. Over the last twelve months the business produced roughly €360.8 million in free cash flow, and the projection set assumes that this cash stream grows from that base rather than shrinking. Analysts see free cash flow rising into the late 2020s, with later years extrapolated at gradually slowing growth rates, which is more typical of a mature pharmaceutical group than an early stage pipeline story.

Those cash flow assumptions, when discounted back into today’s money, point to an intrinsic value that the DCF projections suggest is substantially above the current €81.50 share price. The key question for anyone looking at Orion Oyj is whether those forward cash figures feel reasonable given its ability to turn research into products and recurring earnings, because the model’s outcome is highly sensitive to that path. For readers who want to see the detailed DCF outputs and how they translate into an estimate of Orion Oyj’s intrinsic worth, head to the full calculation. Find out what Orion Oyj could be worth using our Discounted Cash Flow (DCF) estimate.

The Orion Oyj Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Orion Oyj valuation puzzle leaves off, by spelling out what would need to happen with Orion Oyj's growth, margins and earnings for the stock to be worth materially more or materially less than today's price, and they sit on Simply Wall St's Community page. Rather than relying on a single multiple or DCF output, each Narrative lays out the assumptions behind its view of fair value so you can compare them with Orion Oyj's reported results over time.

Community views on Orion Oyj are split between those who see a bit more value left in the current price and those who think expectations already look full.

Bull case: 5% undervalued

"Expansion of Nubeqa into metastatic hormone sensitive prostate cancer in Europe, together with a higher royalty tier already reached in Q3 2025..."

Discover why this Narrative puts Orion Oyj at 5% undervalued.

Bear case: 6% overvalued

"Given the current share price of €81.6, the analyst price target of €76.67 is 6.4% lower..."

Explore why this Narrative puts Orion Oyj at 6% overvalued.

For Orion Oyj, the share price is only one piece of the decision

Before you rely too heavily on any cash flow model for Orion Oyj, it is worth asking who is steering the business, how their interests line up with yours, and what that pay structure really looks like. See who runs Orion Oyj and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com